gemfibrozil has been researched along with simvastatin in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.13) | 18.7374 |
| 1990's | 38 (39.58) | 18.2507 |
| 2000's | 40 (41.67) | 29.6817 |
| 2010's | 14 (14.58) | 24.3611 |
| 2020's | 1 (1.04) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eichinger, M; Feussner, G; Ziegler, R | 1 |
| Foo, WM; Lim, MC | 1 |
| Neuman, HR; Neuman, J; Neuman, MP | 1 |
| Tikkanen, MJ; Tilly-Kiesi, M | 1 |
| Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G | 1 |
| Shapiro, DR; Walker, JF | 1 |
| Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L | 1 |
| Carlson, LA | 1 |
| Bocanegra, TS; Cook, T; Tikkanen, MJ; Walker, JF | 1 |
| Mölgaard, J; Olsson, AG | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Castro Cabezas, M; De Bruin, TW; Erkelens, DW; Kock, LA | 1 |
| Bredie, SJ; de Bruin, TW; Demacker, PN; Kastelein, JJ; Stalenhoef, AF | 1 |
| Johansson, J; Lithell, H; Ohrvall, M; Vessby, B | 1 |
| Lu, ZL | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Baigts, F; Devulder, B; Lecerf, JM; Luc, G | 1 |
| Cramb, R; Head, A; Jakeman, PM; Kendall, MJ; Maxwell, S | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
| Coulter, DM | 1 |
| Bredie, SJ; de Bruin, TW; Kastelein, JJ; Knipscheer, HC; Stalenhoef, AF; Westerveld, HT | 1 |
| Akçiçek, F; Alev, M; Atabay, G; Basçi, A; Duman, S; Kürsad, S; Ok, E; Unsal, A | 1 |
| Glueck, CJ; Lang, JE; Wang, P | 1 |
| Aumont, MC; Seknadji, P | 1 |
| Du Buf-Vereijken, PW; Spooren, PF; van Doormaal, JJ; van Puijenbroek, EP | 1 |
| Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
| Haffner, SM | 1 |
| Barter, P; Clifton, P; Colquhoun, D; Hamilton-Craig, I; Nestel, P; Sikaris, K; Simons, L; Sullivan, D | 1 |
| Isley, W; Rajeshawari, M; Tal, A | 1 |
| Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
| Bruckert, E | 1 |
| Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ | 1 |
| Sinzinger, H | 1 |
| Beggs, PW; Clark, DW; Coulter, DM; Williams, SM | 1 |
| Chee, YC; Tay, JC | 1 |
| Guyton, JR | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Cenarro, A; Civeira, F; Ferrando, J; Garcia-Otín, AL; Mozas, P; Pocoví, M; Puzo, J | 1 |
| Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD | 1 |
| Cattin, L; Donega, P; Fellin, R; Fonda, M; Gasparrini, S; Marotta, G; Passaro, A; Pauciullo, P; Piliego, T; Vigna, GB; Zanca, R | 1 |
| Backman, JT; Kivistö, KT; Kyrklund, C; Neuvonen, PJ; Wang, JS | 1 |
| Black, DM | 1 |
| Plutzky, J; Ridker, PM | 1 |
| Dunlay, R; Koch, M; Lund, RJ; Meares, AJ; Oldemeyer, JB | 1 |
| Harangi, M; Paragh, G | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Tallis, GA | 1 |
| Bastani, B; Germain, MJ; Heim-Duthoy, KL; Kasiske, BL; Singer, GG; Watschinger, B | 1 |
| Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Haenni, A; Lithell, H; Ohrvall, M | 1 |
| Federman, DG; Hussain, F; Walters, AB | 1 |
| Liu, X; She, M; Zhou, Y | 1 |
| Platts, J | 1 |
| Limanni, A; Maxa, JL; Melton, LB; Ogu, CC; Sills, MN | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Baillie, TA; Lin, JH; Liu, L; Ma, B; Pearson, PG; Prueksaritanont, T; Qiu, Y; Roadcap, BA; Tang, C; Zhao, JJ | 1 |
| Karpe, F | 1 |
| Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
| Borghi, C; Dormi, A; Gaddi, A; Sangiorgi, Z; Veronesi, M | 1 |
| Ganda, OP | 1 |
| Rosenson, RS | 1 |
| Brunner, J; Lin, JH; Michel, K; Mu, L; Prueksaritanont, T; Qiu, Y; Richards, KM | 1 |
| Amir, K; Ashraf, R; Shaikh, AR | 1 |
| Farswan, M; Rathod, SP; Semwal, A; Upaganlawar, AB | 1 |
| Bloomgarden, ZT | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Movahed, MR; Samsamsharaiat, SA | 1 |
| Brun, ME; Funk, C; Noé, J; Portmann, R | 1 |
| Doncheva, NI; Nikolov, KV; Vassileva, DP | 1 |
| Gratsianskii, NA; Vaulin, NA | 1 |
| Anzivino, C; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Kienle, MG; Loria, P; Pellegrini, E; Ricchi, M; Zambianchi, L | 1 |
| Baker, E; Cummins, D; Mackey, M | 1 |
| Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA | 1 |
| Chuengsamarn, S; Kaufman, L; Rattanamongkoulgul, S; Suwanwalaikorn, S; Wattanasirichaigoon, S | 1 |
| Anetseder, M; Hager, M; Metterlein, T; Roewer, N; Schuster, F; Tadda, L | 1 |
| Chockalingam, A; Kar, S | 1 |
| Alford, JC; Allen, RR; Nair, KV; Saseen, JJ | 1 |
| Fan, J; Jiang, L; Kong, X; Li, Z; Wu, T; Yuan, H | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Blais, JE; Chan, EW; Tomlinson, B; Wan, EYF; Wong, ICK; Wong, WCW; Ye, X | 1 |
15 review(s) available for gemfibrozil and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 1996 |
[Treatment of familial combined hyperlipidemia].
Topics: Clinical Protocols; Clofibric Acid; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Nicotinic Acids; Simvastatin | 1997 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Ischemia; Pravastatin; Risk Factors; Simvastatin; Smoking | 2001 |
Postprandial lipemia--effect of lipid-lowering drugs.
Topics: Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Postprandial Period; Simvastatin | 2002 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides | 2005 |
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Risk Factors; Simvastatin | 2005 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.
Topics: Acute Kidney Injury; Aged, 80 and over; Coronary Artery Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Myocardial Infarction; Renal Dialysis; Rhabdomyolysis; Simvastatin | 2013 |
Lipid-lowering agents for nephrotic syndrome.
Topics: Adult; Child; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Nephrotic Syndrome; Randomized Controlled Trials as Topic; Simvastatin | 2013 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
31 trial(s) available for gemfibrozil and simvastatin
| Article | Year |
|---|---|
The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Topics: Adult; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Hyperlipoproteinemias; Lipids; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Simvastatin; Triglycerides | 1992 |
Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Random Allocation; Simvastatin | 1989 |
Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Topics: Adult; Apolipoproteins B; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Simvastatin; Triglycerides | 1995 |
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibrozil; Glucose Tolerance Test; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipoprotein Lipase; Lipoprotein(a); Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
[Clinical evaluation of simvastatin in the treatment of hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
[Comparison of the efficacy between simvastatin and gemfibrozil in primary hypercholesterolemia].
Topics: Adult; Aged; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Blood Pressure; Energy Metabolism; Exercise; Exercise Test; Exercise Tolerance; Fatty Acids, Nonesterified; Gemfibrozil; Heart Rate; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lovastatin; Male; Oxidation-Reduction; Oxygen Consumption; Pyrazines; Random Allocation; Simvastatin; Single-Blind Method | 1993 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Topics: Adult; Aged; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Diet, Fat-Restricted; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Simvastatin; Triglycerides | 1996 |
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cross-Over Studies; Dietary Fats; Gemfibrozil; Genotype; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipids; Lipoprotein(a); Lipoproteins; Lovastatin; Predictive Value of Tests; Simvastatin; Triglycerides | 1997 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Finland; Gemfibrozil; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1998 |
Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
Topics: Adult; Apolipoproteins; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Simvastatin; Treatment Outcome | 1999 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides | 1999 |
Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
Topics: Adult; Aged; Area Under Curve; Blood Coagulation; Cholesterol; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Italy; Lipoproteins; Male; Middle Aged; Multivariate Analysis; Postprandial Period; Simvastatin; Triglycerides | 1999 |
Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Microsomes, Liver; Simvastatin | 2000 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
The effects of lipid-lowering agents on acute renal allograft rejection.
Topics: Adult; Aspartate Aminotransferases; Cadaver; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Creatinine; Female; Gemfibrozil; Graft Rejection; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Transplantation; Living Donors; Male; Middle Aged; Placebos; Simvastatin; Time Factors; Tissue Donors; Transplantation, Homologous; Triglycerides | 2001 |
Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Magnesium; Simvastatin | 2001 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Cholestyramine Resin; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Simvastatin | 2004 |
Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Risk Factors; Simvastatin; Time Factors; Triglycerides | 2005 |
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Topics: Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2006 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Topics: Aged; Bone Density; Bone Diseases, Metabolic; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Osteogenesis; Patient Selection; Prospective Studies; Simvastatin; Treatment Outcome | 2010 |
50 other study(ies) available for gemfibrozil and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
Topics: Cost-Benefit Analysis; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Topics: Adult; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
[A case of familial hypercholesterolemia with therapeutic difficulties].
Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin | 1990 |
[Therapeutic possibilities of a newly registered lipid suppressor].
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Lovastatin; Simvastatin | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Child; Cholesterol; Drug Therapy, Combination; Fasting; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Reasons for stopping drugs are monitored in New Zealand.
Topics: Adverse Drug Reaction Reporting Systems; Bezafibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; New Zealand; Product Surveillance, Postmarketing; Simvastatin | 1996 |
Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.
Topics: Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Indoles; Lovastatin; Male; Middle Aged; Neuromuscular Diseases; Simvastatin; Thyroxine | 1996 |
Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil.
Topics: Drug Synergism; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Rhabdomyolysis; Risk; Simvastatin | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Diabetic Angiopathies; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Triglycerides | 1997 |
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Muscular Diseases; Rhabdomyolysis; Simvastatin | 1997 |
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Topics: Bezafibrate; Cohort Studies; Comorbidity; Diabetes Complications; Female; Gemfibrozil; Humans; Hypertension; Lipids; Male; Myocardial Ischemia; New Zealand; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Random Allocation; Retrospective Studies; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome | 1999 |
Drug treatment of hypercholesterolaemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Practice Guidelines as Topic; Simvastatin; Triglycerides | 1998 |
Treatment of type III hyperlipoproteinemia.
Topics: Apolipoproteins E; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Simvastatin; Treatment Outcome | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Statins for stroke: the second story?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pravastatin; Risk Factors; Simvastatin; Stroke | 2001 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis; Simvastatin | 2000 |
Normocholesterolaemic dyslipidaemia: is there a role for fibrates?
Topics: Algorithms; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Decision Trees; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Patient Selection; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Fatal rhabdomyolysis caused by lipid-lowering therapy.
Topics: Aged; Drug Interactions; Fatal Outcome; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Rhabdomyolysis; Simvastatin | 2001 |
Molecular basis for the effect of lipid lowering drugs on growth factors after de-endothelialization.
Topics: Animals; Cholesterol; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Gemfibrozil; Growth Substances; Hypolipidemic Agents; Immunohistochemistry; Male; Platelet-Derived Growth Factor; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Triglycerides; Tunica Intima | 2001 |
Therapy and clinical trials.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis | 2002 |
Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
Topics: Antifungal Agents; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fatal Outcome; Gemfibrozil; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Itraconazole; Male; Middle Aged; Mixed Function Oxygenases; Organ Transplantation; Rhabdomyolysis; Risk Assessment; Simvastatin | 2002 |
Mechanistic studies on metabolic interactions between gemfibrozil and statins.
Topics: Administration, Oral; Animals; Area Under Curve; Catalysis; Dogs; Drug Interactions; Gemfibrozil; Glucuronides; Glucuronosyltransferase; Humans; Hydrolysis; Hypolipidemic Agents; Isoenzymes; Microsomes, Liver; Oxidation-Reduction; Simvastatin | 2002 |
Effects of fibrates on metabolism of statins in human hepatocytes.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Dogs; Gemfibrozil; Hepatocytes; Humans; Hydrolysis; Hypolipidemic Agents; Infusions, Intravenous; Liver; Simvastatin | 2005 |
Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats.
Topics: Animals; Antioxidants; Blood Urea Nitrogen; Catalase; Coenzymes; Creatinine; Female; Gemfibrozil; Glutathione; Humans; Hypolipidemic Agents; Lipid Peroxidation; Oxidants; Oxidative Stress; Rats; Rats, Wistar; Renal Insufficiency; Rhabdomyolysis; Simvastatin; Superoxide Dismutase; Ubiquinone | 2005 |
2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Drug Therapy, Combination; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Quinolines; Simvastatin; Triglycerides | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Reproducible tendinitis-like symptoms related to statin therapy.
Topics: Adult; Aged; Gemfibrozil; Humans; Hyperlipidemias; Male; Simvastatin; Tendinopathy | 2006 |
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Topics: Animals; Anticholesteremic Agents; Biological Transport; Cell Line; CHO Cells; Chromans; Cricetinae; Cricetulus; Drug Interactions; Estrone; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pravastatin; Protein Binding; Recombinant Proteins; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Taurocholic Acid; Thiazolidinediones; Troglitazone | 2007 |
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Complement C4; Data Interpretation, Statistical; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Reference Standards; Simvastatin | 2008 |
Recovery time in a case of gemfibrozil and simvastatin-associated rhabdomyolysis.
Topics: Acute Kidney Injury; Aged, 80 and over; Creatine Kinase; Creatinine; Drug Therapy, Combination; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Rhabdomyolysis; Simvastatin | 2009 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids; Inflammation; Male; Metabolic Syndrome; Microcirculation; Muscle, Skeletal; Nitric Oxide; Probucol; Pyrroles; Rats; Rats, Zucker; Simvastatin; Time Factors | 2009 |
Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals.
Topics: Animals; Atorvastatin; Biopsy; Calcium; Electric Stimulation; Female; Gemfibrozil; Genotype; Heptanoic Acids; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Isometric Contraction; Male; Malignant Hyperthermia; Muscle, Skeletal; Phenotype; Pyrroles; Rhabdomyolysis; Simvastatin; Swine; Time Factors | 2010 |
Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Labeling; Drug Therapy, Combination; Dyslipidemias; Female; Fibric Acids; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Off-Label Use; Practice Patterns, Physicians'; Retrospective Studies; Simvastatin; United States; United States Food and Drug Administration | 2012 |
Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients.
Topics: Cohort Studies; Coronary Disease; Female; Gemfibrozil; Humans; Male; Primary Health Care; Primary Prevention; Retrospective Studies; Simvastatin | 2022 |